Novavax market cap is $15.5 b, and annual revenue was $475.6 m in FY 2020

Novavax Net income (Q1, 2021)-222.7 M

Novavax EBIT (Q1, 2021)-208.6 M

Novavax Cash, 31-Mar-20212 B

Novavax EV13.9 B

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 14.7m | 22.1m | 20.9m | 30.7m | 36.3m | 15.4m | 31.2m | 34.3m | 18.7m | 475.6m |

| 4182% | 50% | (5%) | 47% | 18% | (58%) | ||||

## Cost of goods sold | 7.0m | 14.7m | 8.2m | 15.0m | ||||||

## Gross profit | 7.7m | 7.4m | 12.7m | 15.7m | ||||||

| 52% | 33% | 61% | 51% | ||||||

## R&D expense | 17.9m | 26.1m | 50.3m | 79.4m | 162.6m | 237.9m | 168.4m | 173.8m | 113.8m | 747.0m |

## General and administrative expense | 11.4m | 11.0m | 14.8m | 19.9m | 30.8m | 46.5m | 34.5m | 34.4m | 34.4m | 145.3m |

## Operating expense total | 29.3m | 37.0m | 65.1m | 99.4m | 193.5m | 284.5m | 202.9m | 208.2m | 148.3m | 892.3m |

## EBIT | (21.6m) | (29.7m) | (52.4m) | (83.7m) | (157.2m) | (269.1m) | (171.7m) | (173.9m) | (120.6m) | (416.7m) |

| (147%) | (134%) | (251%) | (273%) | (434%) | (1753%) | (551%) | (507%) | (646%) | (88%) |

## Interest expense | 9.0k | 32.0k | ||||||||

## Investment income | 136.0k | 165.0k | 187.0k | 286.0k | 660.0k | 2.1m | 1.9m | 2.7m | 1.5m | 1.0m |

## Pre tax profit | (19.0m) | (28.5m) | (52.0m) | (82.9m) | (156.9m) | |||||

## Income tax expense | 412.0k | 25.0k | ||||||||

## Net Income | (19.4m) | (28.5m) | (52.0m) | (82.9m) | (156.9m) | (280.0m) | (183.8m) | (184.7m) | (132.7m) | (418.3m) |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Cash | 14.1m | 17.4m | 119.5m | 32.3m | 93.1m | 144.4m | 106.3m | 70.2m | 78.8m | 553.4m |

## Accounts Receivable | 2.0m | 1.0m | 1.9m | 7.5m | 2.3m | 233.0k | 7.5m | 262.0m | ||

## Prepaid Expenses | 2.4m | 2.6m | 17.8m | 16.3m | 8.0m | 181.3m | ||||

## Inventories | 9.2m | 19.3m | 21.8m | |||||||

## Current Assets | 26.1m | 50.4m | 145.0m | 188.2m | 287.3m | 287.8m | 203.3m | 119.3m | 97.2m | 1.2b |

## PP&E | 6.9m | 11.5m | 14.3m | 19.7m | 32.3m | 40.2m | 36.0m | 28.4m | 11.4m | 180.0m |

## Goodwill | 33.1m | 33.1m | 59.5m | 54.6m | 53.1m | 51.7m | 53.6m | 52.0m | 51.2m | 135.4m |

## Total Assets | 66.6m | 102.3m | 235.9m | 276.0m | 386.0m | 394.3m | 302.5m | 208.0m | 173.0m | 1.6b |

## Accounts Payable | 2.6m | 3.2m | 6.0m | 12.9m | 11.9m | 5.7m | 5.6m | 9.3m | 2.9m | 54.3m |

## Short-term debt | 20.0k | (157.0k) | 5.1m | 8.9m | ||||||

## Current Liabilities | 7.6m | 11.7m | 18.9m | 34.1m | 76.5m | 66.4m | 73.7m | 45.5m | 25.8m | 579.7m |

## Long-term debt | 300.0k | 237.0k | 320.6m | 362.1m | ||||||

## Total Debt | 320.0k | 80.0k | 317.8m | 319.2m | 325.7m | 371.0m | ||||

## Total Liabilities | 12.7m | 22.1m | 399.8m | 404.2m | 375.9m | 359.0m | 955.3m | |||

## Common Stock | 1.2m | 1.5m | 3.2m | 3.8m | 324.0k | 714.0k | ||||

## Preferred Stock | ||||||||||

## Additional Paid-in Capital | 383.9m | 438.9m | 612.9m | 729.4m | 951.6m | 936.0m | 1.0b | 1.1b | 1.3b | 2.5b |

## Retained Earnings | (329.7m) | (358.2m) | (410.1m) | (493.1m) | (650.0m) | (930.0m) | (1.1b) | (1.3b) | (1.4b) | (1.9b) |

## Total Equity | 53.8m | 80.2m | 203.2m | 229.6m | 292.7m | (5.5m) | (101.7m) | (167.9m) | (186.0m) | 627.2m |

## Debt to Equity Ratio | -3.1 x | -1.9 x | ||||||||

## Debt to Assets Ratio | 1.1 x | 1.5 x | ||||||||

## Financial Leverage | 1.2 x | 1.3 x | 1.2 x | 1.2 x | 1.3 x | -71.1 x | -3 x | -1.2 x | -0.9 x | 2.5 x |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (19.4m) | (28.5m) | (52.0m) | (82.9m) | (156.9m) | (280.0m) | (183.8m) | (184.7m) | (132.7m) | (418.3m) |

## Depreciation and Amortization | 1.6m | 1.7m | 2.6m | 4.4m | 6.0m | 8.5m | 9.8m | 8.2m | 5.7m | 4.9m |

## Accounts Receivable | (1.9m) | 954.0k | 2.1m | 245.9m | ||||||

## Accounts Payable | (2.7m) | 2.0m | 4.2m | 14.0m | 9.1m | (4.8m) | 5.2m | (6.7m) | (11.5m) | 163.2m |

## Cash From Operating Activities | (23.6m) | (18.2m) | (45.4m) | (87.1m) | 60.8m | (255.5m) | (138.7m) | (184.8m) | (136.6m) | (42.5m) |

## Purchases of PP&E | (610.0k) | (4.3m) | (4.2m) | (1.4m) | (1.9m) | (54.6m) | ||||

## Capital Expenditures | (5.8m) | (7.3m) | (18.3m) | (18.2m) | ||||||

## Cash From Investing Activities | 18.5m | (32.3m) | 16.4m | (129.8m) | (21.3m) | 28.0m | 36.0m | 28.6m | 38.5m | (377.8m) |

## Short-term Borrowings | (473.0k) | (671.0k) | (395.0k) | (600.0k) | ||||||

## Long-term Borrowings | (104.0k) | (37.0k) | (96.1m) | |||||||

## Cash From Financing Activities | 11.1m | 53.8m | 131.0m | 109.7m | 208.3m | 279.0m | 64.5m | 102.8m | 98.4m | 984.8m |

## Net Change in Cash | 6.0m | 3.3m | (38.0m) | (53.5m) | 221.0k | 566.6m | ||||

## Interest Paid | 20.0k | 12.2m | 12.2m | 12.2m | 13.7m | |||||

## Free Cash Flow | (51.1m) | (94.4m) | 42.5m | (273.7m) |

- Source: SEC Filings

- Source: SEC Filings

USD | Q2, 2011 |
---|---|

## Financial Leverage | 1.2 x |

FY, 2016 | |
---|---|

## Patents (US) | 250 |

## Phase I Trials Products | 2 |

## Phase II Trials Products | 1 |

## Phase III Trials Products | 1 |

## Pre-Clinical Phase Products | 3 |

- Source: SEC Filings